Chun Li, Ph.D.
Cancer Systems Imaging
Research activities in the laboratory of Chun Li, Ph.D. are primarily focused on two areas: 1) the development of targeted imaging probes for noninvasive characterization of molecular events associated with tumor progression and regression and 2) the development of novel drug-delivery systems for selective delivery of diagnostic and therapeutic agents.
Molecular imaging probes used in nuclear, optical and magnetic resonance imaging modalities are designed to enhance the sensitivity and selectivity of early tumor detection, tumor-marker profiling and the monitoring of early treatment responses.
Targeted drug delivery, on the other hand, uses nanometric drug carriers to selectively deliver anticancer agents to the tumor to maximize their therapeutic efficacy and minimize their toxic side effects to the normal tissues. Their long-term goal is to apply the “seek and treat” strategy in the development of targeted imaging/therapeutic agents that will eventually be translated to the clinic to improve the management of cancer through early tumor detection and individualized therapy.
Principal Investigator, 1.44 months, John S. Dunn Foundation Chemistry Laboratory for Imaging Sciences, John S. Dunn Foundation, 7/1/2007-6/30/2017
Principal Investigator, 2.4 months, Targeted delivery of cyclopamine by biodegradable core-crosslinked polymeric micelles for radio-chemotherapy of pancreatic cancer, Skip Viragh Foundation, 7/1/2012-6/30/2017
Co-Principal Investigator, 1.2 months, Multifunctional hollow gold nanospheres for concurrent photothermal - chemotherapy, 1R44CA196025-01, NIH/NCI, 5/1/2015-4/30/2017
Mentor, Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology, 1T32CA196561-01, NIH/NCI, PI - Sokolov, 9/1/2015-8/31/2020
Principal Investigator-MDACC, 1.2 months, Simultaneous Ablation of Tumor Cells and Tumor Stromal Cells to Enhance Antitumor against Pancreatic Ductal Adenocarcinoma, Gillson Longenbaugh Foundation, 7/1/2016-6/30/2017
Principal Investigator, 0.12 months, Selective Photothermal Ablation of HCC with Renal Clearable [64Cu]CuS Nanodots, General Electric-Center for Advanced Biomedical Imaging (CABI) - MD Anderson Cancer Center, 7/1/2016-6/30/2018
Principal Investigator, Mechanisms of action of a highly efficacious PGA-Taxol conjugate, 1-R29 CA74819, NIH/NCI, 7/1/1997-6/30/2002
Co-Investigator, Development of poly(L-glutamic acid)-Phase I, R44 CA80589, NIH/NCI, PI - Wallace, 4/15/1999-3/31/2000
Principal Investigator, Radiation induced chemosensitization: potentiation of antitumor activity of polymer-drug conjugate, DAMD17-00-1-0314, US Army Medical Research and Materiel Command, 3/1/2000-2/1/2003
PI-Development Research Award, Targeted assessment of antiangiogenic therapy, U54 CA90810A, NIH/NCI, PI - Abbruzzese, 7/1/2001-6/30/2006
Principal Investigator, Polymeric carriers for molecularly targeted diagnostic agents for near-infrared optical imaging, Texas Higher Education/Advanced Technology Program, 1/1/2002-12/30/2003
Co-Principal Investigator, Development of macromolecular chemotherapeutics, Cell Therapeutics, Inc, 7/1/2002-6/30/2005
Co-PI-Career Development Award, Prostate cancer SPORE, P50 CA90270, NIH/NCI, PI - Logothetis and Lin, 7/31/2002-8/1/2004
Principal Investigator, Assessing angiogenesis by near-infrared imaging, R01 EB00174, NIH/NIBIB, 8/1/2002-7/30/2008
Co-Principal Investigator, Small animal fluorescence-enhanced optical imaging, R01 EB003132, NIH/NIBIB, PI - Sevick-Muraca, 9/16/2003-9/15/2005
Principal Investigator, Site-selective introduction of DTPA-PEG to annexin V for enhanced nuclear imaging of tumor apoptosis, Mike Hogg Foundation, 1/1/2005-1/1/2006
The University of Texas MD Anderson Cancer Center
Cancer Systems Imaging
1881 East Road
Unit Number: 1907
Houston, TX 77054-1901
Room Number: 3SCR4.3636